- Home
- EML vs FATE Comparison
EML vs FATE Comparison
Compare EML & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EML | FATE |
|---|---|---|
| Founded | 1858 | 2007 |
| Country | United States | United States |
| Employees | N/A | 181 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 130.2M | 131.5M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | EML | FATE |
|---|---|---|
| Price | $19.59 | $1.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.92 |
| AVG Volume (30 Days) | 9.5K | ★ 1.6M |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | ★ 2.26% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.19 | N/A |
| Revenue | ★ $258,121,226.00 | $7,137,000.00 |
| Revenue This Year | $1.56 | N/A |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | $18.90 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.49 | $0.66 |
| 52 Week High | $31.67 | $3.43 |
Technical Indicators
Market Signals| Indicator | EML | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 43.87 | 44.31 |
| Support Level | $19.10 | $1.04 |
| Resistance Level | $20.11 | $1.16 |
| Average True Range (ATR) | 0.54 | 0.09 |
| MACD | 0.13 | 0.01 |
| Stochastic Oscillator | 60.83 | 56.10 |
Price Performance
Historical ComparisonAbout EML Eastern Company (The)
The Eastern Co manages industrial businesses that design, manufacture, and sell engineered solutions to industrial markets. The company manages the financial, operational, and strategic performance of its businesses to increase cash generation, operating earnings, and long-term shareholder value. It operates in the United States and Other Countries and generates the majority of its revenue from the United States.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.